Thus, it suggests that PTX3 may become a useful marker to understand the development of fibrosis in patients with NAFLD and a biochemical indicator of increased arterial stiffness in subclinical atherosclerosis. This evidence concerns the gene PTX3 and metabolic dysfunction-associated steatotic liver disease.